Don’t Delay With Delta: Best Practices and Calls to Action in HDV

To link patients with hepatitis delta virus to care, we first must be able to identify them.

Cihan Yurdaydin, MD Released: March 8, 2022

Emerging treatment options for hepatitis delta virus are promising, but we still have more questions than answers regarding the optimal use of these agents around the globe.

Heiner Wedemeyer, MD Released: March 23, 2022

My thinking about HDV testing recommendations has shifted in recent years. Here’s why.

Norah Terrault, MD, MPH Released: May 18, 2022

Our current treatment option for hepatitis delta virus is pegylated interferon alfa, which does not have robust efficacy data and is not always well tolerated—but many novel investigational agents are being studied to provide more efficacious, better tolerated therapies

Paul Y. Kwo, MD Released: August 2, 2022